Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.660
+0.110 (7.10%)
Jun 6, 2025, 4:00 PM - Market closed

Company Description

Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.

It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.

The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California.

Cibus, Inc.
Cibus logo
Country United States
Founded 2010
IPO Date Jul 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 159
CEO Peter Beetham

Contact Details

Address:
6455 Nancy Ridge Drive
San Diego, California 92121
United States
Phone 858 450 0008
Website cibus.com

Stock Details

Ticker Symbol CBUS
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001705843
CUSIP Number 17166A101
ISIN Number US17166A1016
Employer ID 27-1967997
SIC Code 2870

Key Executives

Name Position
Sean O'Connor Ph.D. Senior Vice President and President and Chief Executive Officer of Nucelis
Dr. Peter R. Beetham B.Sc., Ph.D. Co-Founder, Interim Chief Executive Officer, President, Chief Operating Officer and Director
Rory Balfour Riggs M.B.A. Co-Founder and Chairman
Cornelis Broos M.Sc. Interim Chief Financial Officer
Dr. Gregory F. Gocal Ph.D. Co-Founder, Chief Scientific Officer and Executive Vice President
Jason Stokes J.D. Chief Legal Officer, General Counsel and Corporate Secretary
Rosa Cheuk Kim J.D. Senior Vice President of Legal
Dr. James Radtke Ph.D. Senior Vice President of Product Development
Tony Moran Senior Vice President of International Development
Noel Sauer Ph.D. Senior Vice President of Research

Latest SEC Filings

Date Type Title
Jun 6, 2025 8-K Current Report
Jun 6, 2025 424B5 Filing
Jun 4, 2025 8-K Current Report
Jun 4, 2025 424B5 Filing
May 27, 2025 8-K Current Report
May 23, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G Filing
May 8, 2025 10-Q Quarterly Report
May 8, 2025 8-K Current Report
Apr 10, 2025 ARS Filing